Brief: Oncopeptides Publishes Phase 2 Bridge Study Results In Clinical Lymphoma, Myeloma, Leukemia
20/05/2026 13:16
May 20 (Reuters) - Oncopeptides AB ONCO.ST: PUBLISHES PHASE 2 BRIDGE STUDY RESULTS IN CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA PK DATA VALIDATE 30 MG PEPASTXI STARTING DOSE FOR MODERATE RENAL IMPAIRMENT PATIENTS WITH MODERATE RENAL IMPAIRMENT ACHIEVE UP TO 70% ORR WITH PEPASTXI NO NEW SAFETY SIGNALS OBSERVED WITH PEPASTXI IN RENAL IMPAIRMENT PATIENTS Source text: ID:nMFN7LQCzL Further company coverage: ONCO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy